Company Overview and News
Earlier this year, I initiated active coverage of GAIN (8.2% yield) and its preferred stocks GAINM (6.2% yield) and now its newly issued GAINL (6.3% yield).
AIY AINV CLA GAIN GAINM MCQ KAP PNNT BKCC MCV PFLT OSLE GADDP GAINL GLADO HTGZ KCAP GLAD ABDC MSCA CPTA MCC TCRX ARCC HCAPL FSIC MAIN TCPC AIB TCRD TCRZ PSEC HTGX NMFC HTGY TSLF OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC PBB PNTA
Following continued requests due to recent earnings, Part 1 of this article analyzes PSEC's dividend sustainability by performing three tests based on recent (and projected) quarterly results.
ARCC MAIN GAIN GAINM GADDP PSEC NEWTZ ARU MSCA.CL SLRC MSCA TSLX NEWT NEWTL PBB SLRA MO
Part 2 of this article compares MAIN’s recent dividend per share rates, yield percentages, and several other dividend sustainability metrics to fourteen other BDC peers.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSL MSCA.CL MCX BLK MDLY NEWTL PBB
Following multiple requests, this “supplemental” article compares PSEC’s recent quarterly change in NAV, quarterly and trailing twelve-month economic return, NII, and current valuation to 14 BDC peers.
AIY AINV GAIN MCQ GAINM MCV PFLT OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC MAIN TCPC AIB PSEC NEWTZ ARU OCSL MSCA.CL MCX BLK NEWTL PBB
MCLEAN, Va., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Gladstone Investment Corporation (NASDAQ:GAIN) (the “Company”) announced today that on September 6, 2018 its board of directors declared a combined cash distribution of $0.17265625 per share of the Company’s 6.375% Series E Cumulative Term Preferred Stock (“Series E Term Preferred Stock”) for the prorated period from and including the Series E Term Preferred Stock issuance date (August 22, 2018) to and including August 31, 2018, plus the full month of September 2018, payable on September 28, 2018 to record holders as of September 19, 2018.
GAIN GAINM GADDP
There is no incredible value created by the series of articles covering fixed income products whose Call Option was finally, or perhaps timely, exercised by the issuing company. However, it turns out that not all of us have the resources and time to keep track of their portfolio, thus we are continuing our coverage of these events
GAIN TCC GAINM TCAP TCCB TCCA BBDC GADDP
Most BDCs with higher exposure to oil-related investments have rebounded over the last two quarters partially due to rising oil prices and LIBOR resulting in higher book values and earnings.
AIY AINV GAIN HTF KAP BKCC PFLT BBDC OSLE GLADO KCAP ABDC HTFA TSLX HCAPL FSIC FDUS MAIN AIB TCRD NMFC TSLF MCX HCAP CLA MCQ GAINM HRZN PNNT MCV GADDP CGBD HTGZ GLAD MSCA CPTA MCC TCRX ARCC GARS GBDC TCPC TCRZ HTGX HTGY OCSI ARU OCSL MSCA.CL SUNS HTGC PNTA
Due to the recent change in management, readers have asked if I could take a look at OCSI to determine whether operations have improved enough to currently justify an investment.
ACSF AIY AINV GAIN MCQ GAINM OAK MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX BLK NEWTL PBB
Comparison with all the fixed-rated term securities that pay a fixed rate distribution and have less than 10 years to maturity.
PFF GOOD GAIN GAINM GADDP GAINL GLADO LANDP GOODM GLAD GOODN LAND GOODO GOODP
MCLEAN, Va., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Gladstone Investment Corporation (NASDAQ: GAIN) (the “Company”) today announced the amendment and extension of its credit facility led by KeyBank National Association (“KeyBank”), which includes an increase in facility size, extension of the maturity date, and reduction in pricing.
GAIN GAINM GADDP
MCLEAN, Va., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Gladstone Investment Corporation (Nasdaq: GAIN) (the “Company”) today announced that it closed its previously announced offering of 2,600,000 shares of its newly-designated 6.375% Series E Cumulative Term Preferred Stock due 2025 (the “Series E Term Preferred Shares”) at a public offering price of $25.00 per share. Simultaneously with the closing of the offering, the underwriters exercised in full their option to purchase an additional 390,000 Series E Term Preferred Shares on the same terms to cover over-allotments, resulting in a total issuance of 2,990,000 shares for gross proceeds of approximately $74.
LTS-A NHLD GAIN GAINM LTS GADDP
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET